Phase III, multicenter, double-blind, placebo-controlled clinical study comparing chemoimmunotherapy paclitaxel-carboplatin-oregovomab) versus chemotherapy (paclitaxel-carboplatin-placebo) in patients with epithelial carcinoma of the ovary
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ONCOQUEST PHARMACEUTICALS INC
- Phase: III
- Execution start: 27/05/2021
- End of execution: 30/12/2025
- IP: LUCIA CASTILLO PORTELLANO